To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
Sites must be tier 3 hospitals in China. Investigators will mainly be determined according to the following criteria: * Respiratory physicians working in the respiratory department of tier 3 hospitals * To include the expected number of patients in a maximum of 12 months, physicians should manage a reasonable number of asthma, COPD or ACOS over age 40 with persistent airflow limitation (post-BD FEV1/FVC\<0.7). * Physicians should have patients' spirometric data available in the patient's medical files (post-BD FEV1%pred and post-BD FEV1/FVC). This NIS will collect the data (e.g. medical record, patient or physician-reported data) from about 2000 consecutive outpatients with persistent airflow limitation(post-BD FEV1/FVC\<0.7) in about 20 sites in China for one year. Each site will recruit about 50-150 patients successively. The data will be collected under routine clinical practice. The treatments or examinations will be determined by their treating physicians. The data are expected to reflect the actual situation about ACOS. The study population will be about 2000 outpatients, men or women, over age 40, with a clinical diagnosis of asthma, COPD or ACOS with persistent airflow limitation(post-BD FEV1/FVC\<0.7)in China from Q4,2015 to Q3,2016.
Study Type
OBSERVATIONAL
Enrollment
2,016
Research Site
Beijing, Beijing Municipality, China
Research Site
Chongqing, Chongqing Municipality, China
Research Site
Guangzhou, Guangdong, China
The proportion of ACOS among the patients over age 40 with persistent airflow limitation (post-BD FEV1/FVC<0.7) based on GINA and GOLD 2015 definition
Time frame: one day
- The proportions of COPD and asthma, respectively, among the patients over age 40 with persistent airflow limitation (post-BD FEV1/FVC<0.7) based on GINA and GOLD 2015 definition.
Time frame: one day
- The distributions of the severity of airflow limitation according to GOLD lung function grading based on post-BD FEV1 in patients with ACOS, COPD or asthma.
Time frame: one day
- The distribution of groups according to GOLD 2015 group definition (A,B,C,D) in patients with ACOS or COPD.
Time frame: one day
- The distribution of medication by drug class in patients with ACOS, Asthma and COPD.
Time frame: one day
- The proportions of previous diagnosis as asthma/COPD/chronic bronchitis/emphysema in the ACOS patients.
Time frame: one day
The number of Acute exacerbations history in 12 months before the visit
Time frame: one day
The severity of Acute exacerbations history in 12 months before the visit
Time frame: one day
The days of hospitalization or emergency room visit of Acute exacerbations history in 12 months before the visit
Time frame: one day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Haikou, Hainan, China
Research Site
Zhengzhou, Henan, China
Research Site
Changsha, Hunan, China
Research Site
Hohhot, Inner Mongolia, China
Research Site
Shenyang, Liaoning, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Xi’an, Shanxi, China
...and 3 more locations
Severity of ACOS patients evaluated using CAT (mild, moderate, severe and very severe) in ACOS patients
Time frame: one day
Severity of ACOS patients evaluated using ACQ-5 (complete control, good control and uncontrolled) in ACOS patients
Time frame: one day
Severity of ACOS patients evaluated using mMRC (0, 1, 2, 3 and 4) in ACOS patients
Time frame: one day